At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 5 enrolled
Drug / intervention
Pemetrexeddrug
Likely dose
Pemetrexed 500 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer
Ohio State University Comprehensive Cancer Center·interventional·Posted Feb 17, 2006·Updated Feb 10, 2020
In Brief
A Phase 2 clinical trial evaluating Pemetrexed for Head and Neck Cancer. Completed, enrolled 5 participants across 1 site.
Detailed Summary
This study will estimate overall response rate of pemetrexed in poor risk patients with advanced, metastatic, or recurrent squamous cell carcinoma of the head and neck.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
First PostedFeb 2006
Primary CompletionMay 2008
Study CompletionNov 2008
TodayJul 2026
First PostedFeb 17, 2006
Enrollment StartFeb 1, 2006
Primary CompletionMay 1, 2008
Study CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.4 years ago
Interventions
Pemetrexeddrug
500 mg/m2 IV every 3 weeks for 6 cycles